Q-omics provides the consensus-scored PRSS33 profile across patient tissues and cancer cell-line models. PRSS33 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, PRSS33 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, PRSS33 protein abundance shows 20,702 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BRCA, COAD, and LSCC as cancer lineages where PRSS33 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRSS33 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRSS33 survival associations across molecular data types. PRSS33 RNA expression shows survival associations in the most cancer types (21), followed by mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRSS33 RNA expression–survival associations across cancer types. High PRSS33 expression shows unfavorable associations in BRCA, LGG, SCLC and DLBC, but favorable associations in HNSC and UCEC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for PRSS33 RNA expression.
This table summarizes PRSS33 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for PRSS33. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRSS33 shows lower tumor expression in LUAD, HNSC and LUSC and higher tumor expression in COAD, READ and STAD. The COAD box plot shows higher PRSS33 RNA expression in tumor versus normal tissue (log2 FC = +5.825, t-test p < 0.001).
This table shows molecular features associated with PRSS33 in patient tissues and cancer cell lines. In patient samples, PRSS33 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, PRSS33 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and SKIN.
